laurens Kruidenier
Chief Scientific Officer,
Nilo Therapeutics
Dr. Kruidenier has over 25 years of experience in biotech and pharma. His
career includes prior CSO roles at Cellarity and Prometheus Biosciences (acquired by
Merck for ~$11B), and research leadership positions at Takeda and GSK. He holds a
PhD in Mucosal Immunology. He is a frequent participant in major industry conferences
like the J.P. Morgan Healthcare Conference and BIO International, speaking on drug
discovery, immunology, and R&D strategy.
Sessions
-
23-Jun-202624BCFrom Paper to Program: Advancing Novel Therapeutics in Neuroscience
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}